Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1DBV5)

Drug Name
Dexlansoprazole Drug Info
Synonyms
dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN); Kapidex; KS-1075; Lansoprazole
Indication
Disease Entry ICD 11 Status REF
Erosive esophagitis DA25.0 Approved [1]
Non-erosive gastro-esophageal reflux disease DA22.0 Approved [1]
Peptic ulcer DA61 Approved [2]
NSAID-associated gastric ulcer DA60 Phase 3 [2]
Cross-matching ID
PubChem CID
9578005
ChEBI ID
CHEBI:135931
CAS Number
CAS 138530-94-6
TTD Drug ID
DM1DBV5
VARIDT Drug ID
DR00643
INTEDE Drug ID
DR0469
ACDINA Drug ID
D00187

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric H(+)/K(+) ATPase (Proton pump) TTLOKXP ATP4A_HUMAN; ATP4B_HUMAN Modulator [3]
Gastric H(+)/K(+) ATPase alpha (ATP4A) TTF1QVM ATP4A_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID Highest Status REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Approved [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Approved [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Approved [7]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Gastric H(+)/K(+) ATPase (Proton pump) DTT ATP4A 4.385 5.146 4.062 5.066
Gastric H(+)/K(+) ATPase alpha (ATP4A) DTT ATP4A 4.385 5.146 4.062 5.066
P-glycoprotein 1 (ABCB1) DTP P-GP 7.009 6.988 7.442 8.135
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.867 5.142 5.52 7.08
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Erosive esophagitis
ICD Disease Classification DA25.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Gastric H(+)/K(+) ATPase alpha (ATP4A) DTT ATP4A 1.42E-02 -0.15 -1.5
P-glycoprotein 1 (ABCB1) DTP P-GP 2.16E-04 -1.07E+00 -2.77E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 5.51E-02 1.95E-01 1.20E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 3.90E-02 -3.45E-01 -1.49E+00
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022287.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7208).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Clinical pipeline report, company report or official report of Takeda (2009).
5 A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
6 Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32.
7 Pharmacological and safety profile of dexlansoprazole: a new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66.